Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter???s syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib

Abstract

This report shows that in selected patients with a severe form of neonatal Bartter's syndrome, the new cyclooxygenase-2 inhibitor rofecoxib may control the clinical symptoms of hyperprostaglandin-E syndrome after ineffective indomethacin therapy.